SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)

Condition(s) studied

Investigational drug(s) / intervention(s)

CAA patients data collection: Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.

Study summary

Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease, and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in elderly patients. Although increasingly detected, a number of aspects including the pathophysiology, the clinical and neuroradiological phenotype and the disease course are still under investigation. The incomplete knowledge of the disease limits the implementation of evidence based guidelines on patient's clinical management and the development of treatments able to prevent or reduce disease progression.

The SENECA (SEarchiNg biomarkErs of Cerebral Angiopathy) project is the first Italian multicentre cohort study aimed at better defining the disease natural history and identifying clinical and neuroradiological markers of disease progression. By a multidisciplinary approach and the collection of a large and well phenotyped series and biorepository of CAA patients, the study is ultimately expected to improve the diagnosis and the knowledge of CAA pathophysiological mechanisms.

Eligibility

Primary outcome measure(s)

• Clinical and neuroradiological phenotype — 24 months
  description of the phenotypic characteristics of a large population of CAA patients collected in Italy

Trial sites (1)

More Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials in Italy

Other trials for the same condition